Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.
glucose control
insulin secretion
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
08
03
2021
received:
27
12
2020
accepted:
19
03
2021
pubmed:
15
4
2021
medline:
1
7
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
To identify predictors of response to glucose-lowering therapy in patients with new-onset diabetes and very high HbA1c (>10%). The study included EDICT participants with an initial HbA1c of more than 10% (N = 104). All subjects received a 75-g oral glucose tolerance test (OGTT) before initiation of therapy, and then were randomized to receive: (a) initial triple therapy with metformin, pioglitazone and exenatide versus (b) stepwise conventional therapy with metformin followed by glipizide and then glargine insulin to reduce HbA1c to less than 6.5%. Insulin secretion and insulin resistance were calculated with OGTT-derived indices. Sixty-one per cent of participants in the conventional therapy group achieved HbA1c of less than 6.5% at 6 months without need of insulin therapy compared with 78% in the triple therapy group (P = NS). Insulin secretion at baseline was the strongest predictor of subjects who did not require insulin therapy; a cut point of CPEP Insulin secretion in response to a 75-g OGTT predicts the need for insulin therapy at the time of type 2 diabetes (T2D) diagnosis. A cut point of 1.7 of CPEP
Identifiants
pubmed: 33852204
doi: 10.1111/dom.14383
pmc: PMC8238899
mid: NIHMS1707649
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1631-1639Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK107680
Pays : United States
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Diabetes Care. 2017 Mar;40(3):325-331
pubmed: 28096223
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Diabetologia. 1980 Jan;18(1):23-8
pubmed: 6988263
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Endocr Pract. 2015 Dec;21(12):1403-14
pubmed: 26642101
Diabetes. 1972 Apr;21(4):224-34
pubmed: 4552828
Diabetes Care. 2021 Feb;44(2):433-439
pubmed: 33273042
Diabetes Obes Metab. 2018 Apr;20(4):1075-1079
pubmed: 29227578
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Diabetes Care. 2013 Aug;36 Suppl 2:S162-74
pubmed: 23882042
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2162-2170
pubmed: 28324038
J Clin Invest. 1987 May;79(5):1510-5
pubmed: 3571496
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetes. 2006 Feb;55(2):517-22
pubmed: 16443789
Metabolism. 1982 Feb;31(2):139-42
pubmed: 7043166
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
Diabetes. 2006 May;55(5):1430-5
pubmed: 16644701
Diabetes Care. 2011 Sep;34(9):2041-7
pubmed: 21868779
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
Diabetes. 2012 Feb;61(2):447-53
pubmed: 22275086
Ann Intern Med. 1996 Jan 1;124(1 Pt 2):90-6
pubmed: 8554220
Curr Diabetes Rev. 2015;11(1):2-6
pubmed: 25515340
J Clin Invest. 1987 Oct;80(4):1037-44
pubmed: 3308956
Diabetes. 1985 Mar;34(3):222-34
pubmed: 3882489
Diabetes Obes Metab. 2015 Mar;17(3):268-75
pubmed: 25425451
Perspect Clin Res. 2018 Jul-Sep;9(3):145-148
pubmed: 30090714
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Diabetes Care. 1997 Apr;20(4):621-2
pubmed: 9096990
N Engl J Med. 2008 Oct 9;359(15):1618-20
pubmed: 18843126
Diabetes Care. 2014 Jun;37(6):1751-8
pubmed: 24812433